Tuesday, December 29, 2015
Chimerix Inc said its oral antiviral drug for the treatment of a certain kind of infection in stem cell transplant patients did not meet the main goal in a late-stage study.
Patients taking the drug, brincidofovir, did not experience significant reduction in cytomegalovirus (CMV) infection through week 24 after transplant.
Cytomegalovirus is a member of the herpes virus family and remains a significant cause of viral infections in transplant recipients.
reuters.com
